Allarity Therapeutics, Inc. ALLR
0.84 USD -0.03 (-3.91%)
Regular-session close
0.86 +0.02 +2.26%
Pre-market · Nov 18, 4:19 AM ET
0.8178 Day range 0.8887
0.769 52-week range 1.84
- YTD
- -22.13%
- 1 year
- -24.91%
News
benzinga.com United Natural Foods To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts raised price targets for CG Oncology, Viatris, Rubrik, Allarity, IDACORP, Tyson Foods and Range Resources.benzinga.com Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11.25 Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.
benzinga.com Allarity Therapeutics Confirms Expanded Eligibility For Ongoing Phase 2 Trial In Advanced Ovarian Cancer Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observationsAdds platinum-refractory patients as well as those with hard-to-measure but clinically…
globenewswire.com Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts Investigator-supported move capitalizes on strong enrollment momentum and encouraging early clinical observations
defenseworld.net Allarity Therapeutics (NASDAQ:ALLR) Releases Earnings Results, Misses Expectations By $0.18 EPS Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus…
defenseworld.net Allarity Therapeutics (NASDAQ:ALLR) Releases Quarterly Earnings Results, Misses Expectations By $0.18 EPS Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) issued its earnings results on Friday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of…benzinga.com Allarity Therapeutics Q3 EPS $(0.39) Misses $(0.21) Estimate, Sales $5.000K Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.21) by 85.71 percent. This is a 105.26 percent decrease over…
globenewswire.com Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance - Ended third quarter with $24.1 million in cash and restricted cash - Expects positive fourth quarter earnings between $0.01 and $0.04 per sharebenzinga.com Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
benzinga.com Allarity Therapeutics Terminates $6M Equity Purchase Agreement With Tumim Stone Capital To Pursue Alternative Financing; Says No Early Termination Penalty Is Payable -SEC Filing
benzinga.com Allarity Therapeutics Receives First Contract For Its Development, Validation And Related Laboratory Services From Undisclosed European Biotech Firm Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
